These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2637095)

  • 1. Effects of first and second generation sulphonylureas on cardiotoxicity of strophanthidin in rabbits.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res; 1989 Dec; 12(4):193-7. PubMed ID: 2637095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia.
    Pogátsa G; Koltai MZ; Balkányi I; Dévai I; Kiss V; Köszeghy A
    Acta Physiol Hung; 1988; 71(2):243-50. PubMed ID: 3389169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs.
    Ballagi-Pordány G; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res Clin Pract; 1991 Jan; 11(1):47-52. PubMed ID: 2019235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
    Koltai MZ
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of antidiabetic treatment in ischemic heart diseases].
    Pogätsa G; Simon J; Koltai MZ; Ballagi-Pordány G; Aranyi Z
    Orv Hetil; 1990 Jan; 131(3):119-26. PubMed ID: 2405334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glimepiride on the electrical activity of isolated rabbit heart muscle.
    Ballagi-Pordány G; Németh M; Aranyi Z; Kékesi E; Koltai MZ; Papp G; Pogátsa G
    Arzneimittelforschung; 1992 Feb; 42(2):111-3. PubMed ID: 1610416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of ouabain and acetyl strophanthidin effects in normal and failing cardiac muscle by specific antibody.
    Gold HK; Smith TW
    J Clin Invest; 1974 Jun; 53(6):1655-61. PubMed ID: 4598113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res Clin Pract; 1990 Jan; 8(2):109-14. PubMed ID: 2106423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.
    Jojima T; Suzuki K; Hirama N; Uchida K; Hattori Y
    Diabetes Obes Metab; 2009 Feb; 11(2):143-9. PubMed ID: 18564176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiaggregatory activity of hypoglycaemic sulphonylureas.
    Siluk D; Kaliszan R; Haber P; Petrusewicz J; Brzozowski Z; Sut G
    Diabetologia; 2002 Jul; 45(7):1034-7. PubMed ID: 12136403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["First" and "second" generation sulfonylureas: distinction or difference? (author's transl)].
    Balant L
    Diabete Metab; 1978 Jun; 4(2):135-43. PubMed ID: 98364
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides.
    Pogátsa G; Koltai MZ; Balkányi I; Dévai J; Kiss V
    Eur J Clin Pharmacol; 1985; 28(4):367-70. PubMed ID: 3928386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference of the sulphonylurea antidiabeticum gliquidone with mitochondrial bioenergetics in the rat under in vitro conditions.
    Somogyi J; Vér A; Trója G; Végh E; Bühler C; Hatfaludi F; Csermely P; Popović S
    Acta Physiol Hung; 1995; 83(4):299-312. PubMed ID: 8863893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of the hypoglycaemic sulphonylurea gliquidone. III. Conformational analysis.
    Lins L; Brasseur R; Malaisse WJ
    Pharmacol Res; 1996; 34(1-2):9-10. PubMed ID: 8981549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
    Procacci V; Giovine A; Roberto MG; Di Reda N; Lasorsa G; Vendemiale G; Stufano N; Altomare E
    Boll Soc Ital Biol Sper; 1988 Sep; 64(9):817-24. PubMed ID: 3072977
    [No Abstract]   [Full Text] [Related]  

  • 16. Interference of sulphonylurea antidiabetica with mitochondrial bioenergetics under in vivo conditions.
    Somogyi J; Vér A; Trója G; Végh E; Bányász T; Csermely P; Popović S; Kovács T
    Acta Physiol Hung; 1995; 83(4):313-21. PubMed ID: 8863894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
    Fujitani S; Okazaki K; Yada T
    Br J Pharmacol; 1997 Apr; 120(7):1191-8. PubMed ID: 9105692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diabetes mellitus and its treatment on ventricular arrhythmias complicating acute myocardial infarction.
    Rana JS; Mukamal KJ; Nesto RW; Morgan JP; Muller JE; Mittleman MA
    Diabet Med; 2005 May; 22(5):576-82. PubMed ID: 15842512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ATP-sensitive potassium channels and substances affecting them].
    Pospísilová Y
    Vnitr Lek; 1998 Jul; 44(7):435-8. PubMed ID: 9748883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy.
    Sato T; Nishida H; Miyazaki M; Nakaya H
    Diabetes Metab Res Rev; 2006; 22(5):341-7. PubMed ID: 16444778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.